Journals in Pharmacology
Journals in Pharmacology
Elsevier's Pharmacology collection studies how drugs interact with biological systems to improve health and treat disease. It covers pharmacodynamics, exploring drug effects on biology, and pharmacokinetics, studying how the body affects drugs. Branches like Pharmacogenetics. Essential for pharmacologists, this collection offers invaluable insights into drug interactions, efficacy, and safety, crucial for advancing drug development and improving patient outcomes.
The Lancet
The Lancet is an independent, international general medical journal founded in 1823 by Thomas Wakley. Since its first weekly issue (October 5, 1823), the journal has strived to make science widely available so that medicine can serve, and transform society, and positively impact the lives of people.The Lancet is committed to applying scientific knowledge to improve health and advance human progress. In our weekly issues, and Online First content, we publish some of the best science from the best scientists worldwide, providing an unparalleled global reach and impact on health.- ISSN: 0140-6736
Trends in Pharmacological Sciences
Trends in Pharmacological Sciences (TIPS) is a monthly peer-reviewed reviews journal that publishes reviews and opinions in fields broadly covering pharmacology, pharmacy, pharmaceutics and toxicology. Launched in 1979, TIPS every issue of TIPS contains succinct articles on the most exciting recent developments in pharmacology and therapeutics research. The major areas of research that TIPS is interested in are:Drug discovery and development (drug design, target identification and validation, lead generation, preclinical and clinical drug development, drug delivery, pharmaceutical formulation)Basic and clinical hharmacology (drug mechanisms, receptors, enzymes, ion channels, transporters, different classes of ligands, biomarkers, pharmacokinetics, pharmacodynamics, drug metabolism and pharmacogenetics)The... (gene- based, cell- based, protein-based therapy, other drug modalities, routes of administration, drug classes, drug nomenclature)Drug safety and toxicity (drug- drug interactions, adverse drug reactions, mechanisms of drug toxicity, pharmacovigilance)Ph... pharmacoepidemiology and pharmacoeconomicsTIP... particularly seeks articles that are relevant to one or more of these themes. Additionally, TIPS welcomes articles on biopharma regulatory landscape, science policy and regulation and bioethics.Reviews and opinions published in TIPS are usually invited by the editor, Dr. Kusumika Mukherjee but we welcome suggestions from the community as well. Please contact [email protected] for more information.Visit the Cell Press website for more information about Trends in Pharmacological Sciences - http://www.cell.com/...- ISSN: 0165-6147
Current Opinion in Pharmacology
Current Opinion in Pharmacology (COPHAR) publishes authoritative, comprehensive, and systematic reviews. COPHAR helps specialists keep up to date with a clear and readable synthesis of current advances in pharmacology and drug discovery. Expert authors annotate the most interesting papers from the expanding volume of information published today, saving valuable time and giving the reader insight into areas of importance.COPHAR is part of the Current Opinion and Research (CO+RE) suite of journals and is a companion to the new primary research, open access journal, Current Research in Pharmacology and Drug Discovery (CRPHAR).COPHAR publishes the latest advancements in pharmacological sciences, covering, but not limited to, the following human systems:Cardiovascul... systemsDigestive and excretory systemsEndocrine systemImmune and lymphatic systemsMusculoskelet... systemNervous systemReproductive systemRespiratory systemUrinary and renal systemsAdditionally, COPHAR particularly welcomes submissions related to:CancerImmunomodul... disordersNeurologica... and psychiatric disordersEmerging technologiesGender and agingThe journal builds on Elsevier's reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health.Expertise - Expert authors, who are leaders in their field, are invited to write short review articles in which they present recent developments in their subject and provide short annotations to the papers that they think are most relevant.Comprehensi... - There are 27 high-impact Current Opinion review journals in a range of subjects from food science to green and sustainable chemistry.Impact - In addition to a vast readership, Current Opinion titles enjoy high citations, Impact Factors, and CiteScores.Discovera... Articles get high visibility and maximum exposure on an industry-leading platform that reaches a vast, global audience.Selection of topics to be reviewed Section Editors, who are major authorities in the field, are appointed by the Editors of the journal. They divide their section into a number of topics, ensuring that the field is comprehensively covered and that all issues of current importance are emphasised. Section Editors commission reviews from authorities on each topic that they have selected.Submissions... Opinion in Pharmacology allows two ways to submit to the journal:Invitation – in accordance with the established procedure for all Current Opinion titles, andNEW– authors are given a “spontaneous submission option” via the submission portal “General Pharmacology” at https://www.editoria... to open the journal to the authorship fully.Short Reviews Authors write short review articles in which they present recent developments in their subject, emphasising the aspects that, in their opinion, are most important. In addition, they provide short annotations to the papers that they consider to be most interesting from all those published in their topic over the previous year.Editorial Overview Section Editors write a short overview at the beginning of the section to introduce the reviews and to draw the reader's attention to any particularly interesting developments.Ethics in Publishing: General StatementThe Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it is useful to outline our expectations of authors and the procedures that the journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential; full disclosure to the journal is the safest course. All submissions to the journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the journal not to publish on the basis of the declared conflict.For more information, please refer to: https://www.elsevier...- ISSN: 1471-4892
Phytomedicine
International Journal of Phytotherapy and PhytopharmacologyPub... in affiliation with the European Scientific Cooperative On Phytotherapy (ESCOP) Phytomedicine is primarily a therapy-oriented Journal. Phytomedicine publishes innovative studies on efficacy, safety, quality and mechanisms of action of specified plant extracts, phytopharmaceuticals and their isolated constituents. This includes clinical, pharmacological, pharmacokinetic, and toxicological studies of specified herbal medicinal products, herbal preparations and purified compounds which have a defined and consistent quality assuring reproducible pharmacological activity.Phytomedici... was founded in 1994 to focus and stimulate research in this particular field and to set internationally accepted scientific standards for pharmacological studies, proof of clinical efficacy and safety of phytomedicines.The main aims of Phytomedicine are associated with the integration of phytopreparations into conventional/officia... medicine.The journal covers the following sections:Clinical pharmacology and toxicology (randomized, placebo controlled, double blind, and observational open label studies)Behavioural, mental, affective, and stress-associated disordersAge-associa... disordersNeuropharma... pharmacologyMetaboli... syndrome and obesityCancerImmunop... inflammationInfectio... diseasesPulmonary, gastrointestinal, cardiovascular and urogenital diseasesSystems biologySafety assessment, pre-clinical toxicology, interaction with drugs and adverse events of herbal preparationsPharmaco... of natural compoundsStandardiza... of herbal preparationsLegislat... of botanicalsInvited reviewsThe directions of Phytomedicine are known to provide profound scientific background in Herbal Medicinal Products, their reproducible Quality and evidence based therapeutic efficacy. Since then quality criteria and standardization methods were defined and the European Medical Agency has elaborated numerous guidelines for the conduction of clinical studies and preparation of Herbal Medicinal Products. In total 107 ESCOP monographs have been produced and submitted to EMA. Many new analytical methods and instruments were implemented both for analysis and standardization of herbal Substances, herbal preparations and their bioassays and tremendous work has been carried out to remain aligned with these intentions during the last 18 years.Nowadays important topics remain to be approached, such as harmonization of the regulatory frameworks in Europe, America, Asia and Australia or the legislation of various "botanicals", where strict differentiation of requirements for health claims of herbal medicinal product, dietary supplements and nutraceuticals are required.Phytomedici... is the companion title to the open access journal Phytomedicine Plus.- ISSN: 0944-7113
Prostaglandins & Other Lipid Mediators
Prostaglandins & Other Lipid Mediators is the original and foremost journal dealing with prostaglandins and related lipid mediator substances. It includes basic and clinical studies related to the pharmacology, physiology, pathology and biochemistry of lipid mediators.Prostaglan... & Other Lipid Mediators invites reports of original research, mini-reviews, reviews, and methods articles in the basic and clinical aspects of all areas of lipid mediator research: cell biology, developmental biology, genetics, molecular biology, chemistry, biochemistry, physiology, pharmacology, endocrinology, biology, the medical sciences, and epidemiology. Systematic reviews and meta-analysis studies will not be acceptable for publication.Prostagl... & Other Lipid Mediators also accepts proposals for special issue topics. The Editors will make every effort to advise authors of the decision on the submitted manuscript within 3-4 weeks of receipt.US National Institutes of Health (NIH) voluntary posting ("Public Access") policy Prostaglandins & Other Lipid Mediators and Elsevier facilitate the author's response to the NIH Public Access Policy.- ISSN: 1098-8823
Journal of Controlled Release
The Journal of Controlled Release (JCR) is the Official Journal of the Controlled Release Society, and of the Japan Society of Drug Delivery System.It publishes high-quality research articles in the broad field of delivery science and technology. This includes drug delivery systems and all aspects of formulations, such as physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, in vivo testing, and formulation research and development in the disciplines of pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries.Manuscrip... that advance fundamental understanding of principles and/or demonstrate advantages of novel technologies in safety and efficacy over current clinical standards will be given priority.- ISSN: 0168-3659
Neuropharmacology
Neuropharmacology publishes high quality, original research within the discipline of neuroscience. The emphasis of Neuropharmacology is on the study and understanding of the actions of known exogenous and endogenous chemical agents on neurobiological processes in the mammalian nervous system. Work with non-mammalian and invertebrate species may be considered in exceptional circumstances. The journal does not usually accept clinical research, although neuropharmacological studies in humans may be considered on the condition that they provide novel insight into either the actions of drugs and/or neurobiological mechanisms. The journal only considers submissions in which the chemical structures and compositions of experimental agents are readily available in the literature or disclosed by the authors in the submitted manuscript. Similarly, manuscripts describing the use of natural products will only be considered if the active ingredient is known and disclosed.The journal publishes Special Issues in which leading experts are invited to serve as Guest Editors to compile a collection of reviews, and occasionally original articles, around a particular topical theme in neuroscience research. The list of recent Special Issues can be found here. Suggestions for Special Issues can be made directly to the Editor-in-Chief.Neur... also publishes topical narrative reviews on subjects within its remit. These reviews are commissioned by the Editorial Team or arise after correspondence with potential authors. Unsolicited reviews will be considered, but authors are encouraged to contact the Editor-in-Chief of their intention to submit a review. Potential review authors should clearly indicate in the cover letter their expertise in the area, the timeliness of the topic, and how the review differs from, and adds to, recent published reviews on related topics. Authors are expected to have an established experimental track record in the topic of the review, and should provide full citations, including URLs/DOIs, of recent experimental papers in peer-reviewed journals relevant to the topic of the review in their cover letter. In the absence of an experimental track record, authors should provide a justification for why they believe they are the right persons to author this review article at this point in time. The absence of any such evidence of relevant experimental expertise or an explanation of author appropriateness will result in the return of the manuscript to the authors. On the basis of the case made by authors, potential overlap with planned Neuropharmacology content, and discussions with the Editorial Team, the Editor-in-Chief will provide authors with a prompt decision regarding the proposed review. Systematic reviews, meta- or bibliographic analyses will not be considered unless they are a necessary part of a Special Issue and conducted by experts in the field, and even then only under exceptional circumstances and at the discretion of the Editor-in-Chief.- ISSN: 0028-3908
Pulmonary Pharmacology & Therapeutics
Pulmonary Pharmacology and Therapeutics (formerly Pulmonary Pharmacology) is concerned with lung pharmacology from molecular to clinical aspects. The subject matter encompasses the major diseases of the lung including asthma, cystic fibrosis, pulmonary circulation, ARDS, carcinoma, bronchitis, emphysema and drug delivery. Laboratory and clinical research on man and animals will be considered including studies related to chemotherapy of cancer, tuberculosis and infection. In addition to original research papers the journal will include review articles and book reviews.Research Areas Include:• All major diseases of the lung • Physiology • Pathology • Drug delivery • Metabolism • Pulmonary ToxicologyBefore submitting, please note the "Rules of 5" defining immediate rejection criteria of PPT:1. Out of scope: The paper should report on the use of pharmacological or toxicological studies (positive or negative) that are directly related to Pulmonary Pharmacology & Therapeutics.Immedia... rejection criteria are: a) Testing of extracts or plant parts that are not characterized b) Case Reports or n=1 studies2. Too preliminary: A paper must be based on a thorough and extensive study, using proper controlsImmediate rejection criteria are: a) In vitro studies with a single dose, or very high concentration b) Single dose studies with very few animals, no dose-response studies c) No proper controls. d) Repetition or confirmation of an earlier work3. Unethical: The study must have been carried under appropriate ethical approval for the study (either animal or human).4. Inappropriate experiments or lacking essential detailImmediate rejection criteria are: a) Wrong species or lacking details on the exact number of animals/subjects used b) No details of structure if a new drug is used for the first time5. Lack of novelty: The study must represent a novel approach to the field.Immediate rejection criteria are: a) Repetition of well known data b) No advance of knowledge in the fieldNote that only manuscripts written in good English will be considered by the Editors (British usage is preferred).- ISSN: 1094-5539
Biochemical Pharmacology
Biochemical Pharmacology publishes original research findings and review articles related to the elucidation of cellular and tissue function(s) at the biochemical and molecular levels, the modification of cellular phenotype(s) by genetic, transcriptional/tran... or drug/compound-induce... modifications, as well as the pharmacodynamics and pharmacokinetics of xenobiotics and drugs, the latter including both small molecules and biologics.The journal's target audience includes scientists engaged in the identification and study of the mechanisms of action of xenobiotics, biologics and drugs and in the drug discovery and development process.All areas of cellular biology and cellular, tissue/organ and whole animal pharmacology fall within the scope of the journal. Drug classes covered include anti-infectives, anti-inflammatory agents, chemotherapeutics, cardiovascular, endocrinological, immunological, metabolic, neurological and psychiatric drugs, as well as research on drug metabolism and kinetics. While medicinal chemistry is a topic of complementary interest, manuscripts in this area must contain sufficient biological data to characterize pharmacologically the compounds reported. Submissions describing work focused predominately on chemical synthesis and molecular modeling will not be considered for review.While particular emphasis is placed on reporting the results of molecular and biochemical studies, research involving the use of tissue and animal models of human pathophysiology and toxicology is of interest to the extent that it helps define drug mechanisms of action, safety and efficacy.Reports describing experiments conducted with natural product mixtures, plant or animal extracts will not be considered for publication unless the structures and concentrations of all component substances are known, and the agents can be easily obtained by others wishing to replicate the study.The chemical structure of all novel compounds tested must be included in the submitted manuscript or be readily accessible in the published literature. References to structures in the patent literature must unambiguously identify a single molecular structure. All compounds, reagents, instrumentation and equipment employed in a study must be available from identified commercial suppliers, bio/pharmaceutical companies or from individuals holding legal rights to their use. Submissions will not be considered for publication if the chemical structures of tested compounds are not revealed, generally known, or accessible in the literature.Original research submissions must contain:A rationale for the selection of the compound/drug for study as well as for the concentrations/doses employed. Quantities used for concentration- and dose-response experiments should vary logarithmically, e.g., 1, 3, 10, 30 mg/kg, 0.1, 1.0, 10, 100 nanomolar, etc. Justification must be provided for studying only a single concentration or dose of a compound, especially as it relates to reference standards and antagonists/modulato... of receptors, enzymes and signaling pathways.Justificati... must also be provided for the selection of the statistical tests employed as they relate to the experimental design.It is expected that all findings have been subjected to rigorous quantitative analyses, with the calculation and reporting of IC50, Ki, EC50, etc., values. These must be derived from a minimum of three (3) separate and distinct experiments, with the replicates within any single experiment being averaged to obtain a single value for that experimental series.Manuscripts that fail to meet these criteria will be subject to rejection without peer-review.- ISSN: 0006-2952
Schizophrenia Research
An International Multidisciplinary Journal of the Schizophrenia International Research SocietyAs an official journal of the Schizophrenia International Research Society (SIRS) Schizophrenia Research is THE journal of choice for international researchers and clinicians to share their work with the global schizophrenia research community. More than 6000 institutes have online or print (or both) access to this journal - the largest specialist journal in the field, with the largest readership!Schizophr... Research's time to first decision is as fast as 6 weeks and its publishing speed is as fast as 4 weeks until online publication (corrected proof/Article in Press) after acceptance and 14 weeks from acceptance until publication in a printed issue.The journal publishes novel papers that really contribute to understanding the biology and treatment of schizophrenic disorders; Schizophrenia Research brings together biological, clinical and psychological research in order to stimulate the synthesis of findings from all disciplines involved in improving patient outcomes in schizophrenia.Manusc... with a focus on cognition in schizophrenia can be submitted to the journal's open access companion title, Schizophrenia Research: Cognition.- ISSN: 0920-9964
